Bortezomib (PS-341)

For research use only.

Catalog No.S1013 Synonyms: LDP-341, MLM341

566 publications

Bortezomib (PS-341) Chemical Structure

CAS No. 179324-69-7

Bortezomib (PS-341, LDP-341, MLM341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
USD 1370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bortezomib (PS-341) has been cited by 566 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341, LDP-341, MLM341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NVrTbop7S3m2b4TvfIlkKEG|c3H5 MYq1NEDPxE1? NFzPZ3Y1QCCq MYrEUXNQ NVf2bZNXU2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? MWKxNFQ6QTZ2Mx?=
OVCA 429 NUmzfGtTTnWwY4Tpc44hSXO|YYm= MYizNFAhdk1? M{PUN|Q5KGh? MlGxSG1UVw>? NXG1OI12TGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ MWOxNFk6QTd4Nh?=
RPMI8226 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r0WlExOCCwTR?= M1vFSFQ5KGh? MXnEUXNQ NI[5R3pKSzVyPUOwJI5O MmDINVE{ODZ2OEm=
Dox40 M2PyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxNFAhdk1? MnPPOFghcA>? NFnsUpNFVVOR NVTxcHpWUUN3ME20NEBvVQ>? M2LhVVEyOzB4NEi5
MR20 M2nlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxNFAhdk1? NFTuRWM1QCCq MXTEUXNQ M{W2UmlEPTB;MkCgcm0> NU\UT4RuOTF|ME[0PFk>
LR5 NXHTc5N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPiNVAxKG6P MXG0PEBp M{n5S2ROW09? Mn\nTWM2OD1{MDDuUS=> M4e3cVEyOzB4NEi5
U266 NF7UfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLvbpZ{OTByIH7N NUT6fHo5PDhiaB?= NHfh[o5FVVOR NFnwO21KSzVyPUOgcm0> NGHDXlUyOTNyNkS4PS=>
IM-9 M1\Udmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxNFAhdk1? MUe0PEBp M4\ZTGROW09? M3vFOWlEPTB;NjDuUS=> M3\Y[FEyOzB4NEi5
Hs Sultan MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHSNVAxKG6P NGTwS4c1QCCq MnSwSG1UVw>? M{P1bWlEPTB;MkCgcm0> MXuxNVMxPjR6OR?=
PAM-LY2 NF75XVFHfW6ldHnvckBCe3OjeR?= NVHIN5BiOTByIH7N NYXQfm5[OTJiaB?= M3PFXmROW09? MXTJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= MUixNVM2ODlzMx?=
PAM 212 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fzcVExOCCwTR?= MWK3NkBp M{nFW2ROW09? NFzOc4tKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NUjlVnZKOTF|NUC5NVM>
PAM-LY2 NWrDRo9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[xNFAhdk1? M2jtS|czKGh? Mn2ySG1UVw>? NHvXdZBKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MXGxNVM2ODlzMx?=
B4B8 NGj3VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfoNVAxKG6P NITsOGo4OiCq NIDXWpZFVVOR MV3Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NIPENmUyOTN3MEmxNy=>
B7E3 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmxNFAhdk1? NXfsdZdtPzJiaB?= MXjEUXNQ MXPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXOxNVM2ODlzMx?=
UM-SCC-9 NWLWOVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfYc5pCOTByIH7N MXe3NkBp Mme3SG1UVw>? MmnzTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NH7pfYkyOTN3MEmxNy=>
UM-SCC-11B NEnMW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPhOXkyODBibl2= NWDXZVVXPzJiaB?= NFfDTINFVVOR NVzpW|l5UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MnrnNVE{PTB7MUO=
H460 NUPIPWp5TnWwY4Tpc44hSXO|YYm= MmXRNVAh|ryP NEGzWnczPCCq Ml2xSG1UVw>? MnPFTY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>? MVKxNlQ6OjFzNx?=
U266 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\IOHh5PTByIH7nM41t MVy0PEBp MnPPSG1UVw>? NYPocYVpUW6qaXLpeJMh[2WubDDndo94fGh? Mlr1NVI3OzF4MUm=
ARH77 NWfie2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\DXlUxOCCwZz;tcC=> Ml2wOFghcA>? MUTEUXNQ MUPJcohq[mm2czDj[YxtKGe{b4f0bC=> NHz0SG8yOjZ|MU[xPS=>
WAD-1 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXEfnk2ODBibnevcYw> M2[xRVQ5KGh? Mmf6SG1UVw>? NIHN[HNKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NWPxS3JEOTJ4M{G2NVk>
U266/LR7 NWXKXWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1eXdpPTByIH7nM41t M3;SeFQ5KGh? MnL2SG1UVw>? MVjJcohq[mm2czDj[YxtKGe{b4f0bC=> MXyxNlY{OTZzOR?=
U266/dox4 M1XBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPUXnhiPTByIH7nM41t MoHjOFghcA>? NEfRSVRFVVOR M3SzSWlvcGmkaYTzJINmdGxiZ4Lve5Rp NIjnRpQyOjZ|MU[xPS=>
RPMI8226/LR5 NGHwdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvpfm02ODBibnevcYw> NUK2PJlLPDhiaB?= M2PxXWROW09? Mn;STY5pcWKrdIOgZ4VtdCCpcn;3eIg> MX2xNlY{OTZzOR?=
H460 NFzGVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2OnAyOCEQvF2= NXziSItkPzJiaB?= M4m4[2ROW09? NYLLcHFyUUN3ME2xNFAhdk1? NEK2TIYyOjZ|MU[yNC=>
H358 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrRRZIyOCEQvF2= MnroO|IhcA>? M{HGfGROW09? NHLmNHJKSzVyPUewJI5O M{\DcVEzPjNzNkKw
H322 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexNEDPxE1? NEGxbmc4OiCq MoXRSG1UVw>? NGe1eXRKSzVyPU[yNEBvVQ>? NV[xe5JIOTJ4M{G2NlA>
H460 MmnRSpVv[3Srb36gRZN{[Xl? NEnoOJcyODBibl2= NUGxSZRlOjRiaB?= NHXvOYlFVVOR NUHkZ5dEUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= M2TBPFEzPjNzNkKw
LNCap-Pro5 MofLSpVv[3Srb36gRZN{[Xl? NHOzPFcyKM7:TR?= MkPROEBp MXPEUXNQ M{DDeHN1[WKrbHn6[ZMheDV| MkG0NVQ3OTJ3M{K=
T29 NVXqWJJXSXCxcITvd4l{KEG|c3H5 M{C0PVUxKG6P NVTxeJJjPDhiaDC= NUPjNJBZTE2VTx?= Mkm5TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWXNO3ppOTZ5N{ixO|k>
T29Kt1 NGW0WFBCeG:ydH;zbZMhSXO|YYm= NHfuU202OCCwTR?= MoT4OFghcCB? MoPGSG1UVw>? NGr1SYVKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlHhNVY4PzhzN{m=
HCT116 NYrIZ403SXCxcITvd4l{KEG|c3H5 MnvNOVAhdk1? MVq0PEBpKA>? MVHEUXNQ MXPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NED1OlQyPjd5OEG3PS=>
HKe-3 MYHBdI9xfG:|aYOgRZN{[Xl? M1fmUFUxKG6P MnzWOFghcCB? M1;wW2ROW09? NFLLdY1KdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mm\MNVY4PzhzN{m=
NB-1691 NXj0RpRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr6SWU5OSEQvF2= NUftSmw2PzJiaB?= M1K0TGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NEHydGgyPzZ6OU[4OC=>
CHLA-255 NWq1VFd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL6PVgyKM7:TR?= MVe3NkBp NYLjSnhvUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl MY[xO|Y5QTZ6NB?=
SK-N-AS NIPuNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zYXVEh|ryP MVi3NkBp M2PCVWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= MnO0NVc3QDl4OES=
NB-1691 M{DXcGZ2dmO2aX;uJGF{e2G7 NVy3V5hROTBibl2= M1HSPFI1KGh? MV;TbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl NYnzNJV5OTd4OEm2PFQ>
CHLA-255 MlPLSpVv[3Srb36gRZN{[Xl? MVGxNEBvVQ>? MoTmNlQhcA>? M{fOSW1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn MVmxO|Y5QTZ6NB?=
RPMI 8226 NIXRd4NHfW6ldHnvckBCe3OjeR?= NWC1Tm14OjBibl2= MXy4JIg> NXPP[XM6W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MYOxPVQ{PjB3MB?=
MM.1S NEmyfYlHfW6ldHnvckBCe3OjeR?= NUK3dGc1OjBibl2= NH;ndFI5KGh? MlL3V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MYKxPVQ{PjB3MB?=
U266 M13odmZ2dmO2aX;uJGF{e2G7 NYXXTlFDOjBibl2= NXfKXVNGQCCq M1zkdHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MV2xPVQ{PjB3MB?=
OPM1 NYXoNXlqTnWwY4Tpc44hSXO|YYm= MVqyNEBvVQ>? NWHZWnkyQCCq MmjnV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NYPrOY5iOTl2M{[wOVA>
INA6 MYHGeY5kfGmxbjDBd5NigQ>? NXL0O41NOjBibl2= NH\VWHY5KGh? NXvDd2NrW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M3zySVE6PDN4MEWw
OPM2 Mo\ZSpVv[3Srb36gRZN{[Xl? NVrFWHBSOjBibl2= NX\YNGxFQCCq NWDUNox[W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NX7HNpNpOTl2M{[wOVA>
RPMI 8226 MW\GeY5kfGmxbjDBd5NigQ>? MlzKNlAhdk1? MnXRPEBp MUHJcoR2[2W|IFTORUB{gW62aHXzbZM> M2\SeFE6PDN4MEWw
BaF/3 M1XaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj3NVAxKG6P M1zzUVQ5KGh? MlfxTWM2OD14LkKgcm0> Mnj1NlA{ODV4OUK=
BaF/3-p210 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxNFAhdk1? NFXvPHQ1QCCq NWPhW2V1UUN3ME20Mlchdk1? Mmf3NlA{ODV4OUK=
TCC-S MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\kNpAyODBibl2= NHrHb4g1QCCq MXfJR|UxRTJwODDuUS=> NX;NV3U3OjB|MEW2PVI>
BaF/3 MWfGeY5kfGmxbjDBd5NigQ>? NHrZUIE3KG6P MonaOFghcA>? NHfFRVlKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MYSyNFMxPTZ7Mh?=
BaF/3-p210 M3nwSmZ2dmO2aX;uJGF{e2G7 MWW2JI5O M4DkTlQ5KGh? M{jQUWlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NX3lRWhrOjB|MEW2PVI>
BaF/3-p210 MnPQSpVv[3Srb36gRZN{[Xl? MVG2JI5O NVvDR5hqOjRiaB?= M4TaPXJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk NFSxc2QzODNyNU[5Ni=>
Raji MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm5T3FiOSEQvF2= NVyzV2RkOjRiaB?= NFiwUXFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MVyyNVE4ODl6OB?=
LCL-1 NGK3VYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjTbHEyKM7:TR?= M1n0NFI1KGh? M2C2OHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MV[yNVE4ODl6OB?=
LCL-2 NGfXTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXMNUDPxE1? NITM[4QzPCCq M4PrZ3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= Mny1NlEyPzB7OEi=
BJAB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrNNUDPxE1? M1vpflI1KGh? M2DQTXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M1vNNlIyOTdyOUi4
SNT-13 NIC3SJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfVNUDPxE1? Mo\pNlQhcA>? NWfOXIx5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NETQTVAzOTF5MEm4PC=>
SNT-16 M{DVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPZNUDPxE1? NIrERoczPCCq M4\pVXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NHTzXnozOTF5MEm4PC=>
Jurkat NIPPPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWzNUDPxE1? MVKyOEBp NXzGUIlOWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MmO5NlEyPzB7OEi=
KAI-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixJO69VQ>? M4qzXVI1KGh? MVjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MYiyNVE4ODl6OB?=
SNK-6 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xJO69VQ>? M4nmOVI1KGh? NHvlSlhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MXmyNVE4ODl6OB?=
KHYG-1 NUn6RoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\PNUDPxE1? NFLSVoczPCCq NHzEdHdT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MoXQNlEyPzB7OEi=
SNT-16 NXH4XoJQSXCxcITvd4l{KEG|c3H5 MmS4NUDPxE1? MVi2JIg> NIfHRWJKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUO0VGtZOjFzN{C5PFg>
Jurkat NVr5[IV7SXCxcITvd4l{KEG|c3H5 M4XBOFEh|ryP NWW4SJdTPiCq MVnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NGHWTYczOTF5MEm4PC=>
KAI-3 NH71NZFCeG:ydH;zbZMhSXO|YYm= MWCxJO69VQ>? NXfHbGM3PiCq NIW3VJpKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlXONlEyPzB7OEi=
KHYG-1 NHrzOYVCeG:ydH;zbZMhSXO|YYm= M1XZclEh|ryP NYLoZ5hvPiCq Mme5TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXeyNVE4ODl6OB?=
SNT-13 M1rsWmFvfGm4aYLhcEBCe3OjeR?= MmnwNUDPxE1? M1vhVlI1KGh? M1XyNmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MWSyNVE4ODl6OB?=
SNT-16 Mk[zRY51cX[rcnHsJGF{e2G7 M4rtSVEh|ryP MXqyOEBp M2fmeGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? M4KwV|IyOTdyOUi4
KAI-3 NVPBcFVQSW62aY\pdoFtKEG|c3H5 NHi0XW4yKM7:TR?= M1fYVlI1KGh? NV\qdlh2UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MmPPNlEyPzB7OEi=
SNK-6 NXXCZmlySW62aY\pdoFtKEG|c3H5 MlLlNUDPxE1? M2j3NlI1KGh? M37HXGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MVKyNVE4ODl6OB?=
RAW 264.7 NWX1RlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvtNVAxKG6P M{\yS|Q5KGh? MVXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MnTINlI1OjdzNUS=
A375 MnLTRZBweHSxc3nzJGF{e2G7 Mnj4NVAhdk1? MX6yOEBp MVzJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NF;j[VYzOzB5OUC4Ny=>
BLM NYPTWGxvSXCxcITvd4l{KEG|c3H5 MVqxNEBvVQ>? MmnjNlQhcA>? Ml21TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Ml3oNlMxPzlyOEO=
A375 M{izTWF2fG:yaHHnfUBCe3OjeR?= MWKxNEBvVQ>? NGG2WVUyOiCq NXjH[45PUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MnmyNlMxPzlyOEO=
BLM NH20W4NCfXSxcHjh[5khSXO|YYm= MknINVAhdk1? M{LUSlEzKGh? NV;ub2NTUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NWXFU4s6OjNyN{mwPFM>
H1299 M{XkcGFxd3C2b4Ppd{BCe3OjeR?= MUG4NEBvVQ>? MWOyOEBp M{X2W2ROW09? NFzRbmpU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= M3zteFI2OzJ|Nkmz
Hut-78 NGLRTWJHfW6ldHnvckBCe3OjeR?= MUixNFAhdk1? NYO3U4YyOjRiaB?= NIfwV2hFVVOR MlPDSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w NFHTNmMzPTZ6MUOzOS=>
H9 MnHTSpVv[3Srb36gRZN{[Xl? NY\ZSoMzOTByIH7N MnezNlQhcA>? NUjIRXZrTE2VTx?= M3TJU2Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= MXOyOVY5OTN|NR?=
HH NFLUeJZHfW6ldHnvckBCe3OjeR?= MoLiNVAxKG6P MlnENlQhcA>? NHH3UmZFVVOR MlXG[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w M{K2R|I2PjhzM{O1
Hut-78 NHzCOHZOcWe{YYTpc44hSXO|YYm= MX[xNFAhdk1? MlG5NlQhcA>? MlTnSG1UVw>? NV7pe|NWWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> MkH3NlU3QDF|M{W=
HH Mn3zUYloemG2aX;uJGF{e2G7 Mon6NVAxKG6P NGjyUHMzPCCq NH;G[IFFVVOR MX;S[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFn MoHSNlU3QDF|M{W=
U937 NXfsdIg2TnWwY4Tpc44hSXO|YYm= NHTqUmgyODBibl2= MX[2JIg> M4[yeWlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? NG\MTYwzPTd7MUS3Oy=>
human PBMC NEO0Tm9HfW6ldHnvckBCe3OjeR?= NHK5OG4yODBibl2= M1\K[lI1KGh? NFzHWYlKdmS3Y3XzJGlNNThicnXs[YF{\Q>? NILZbJYzPTd7MUS3Oy=>
ES6 NEL0bVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X4[GlEPTB;MD6wNFIyKG6P M3m2U3NCVkeHUh?=
SK-UT-1 M123PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrwWXRvUUN3ME2wMlE3OyCwTR?= M3XEVXNCVkeHUh?=
SH-4 M4TvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HjW2lEPTB;MD6xO|Mhdk1? MVLTRW5ITVJ?
TE-9 M{HsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1eGt[UUN3ME2wMlE5OiCwTR?= MX7TRW5ITVJ?
A253 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LjdmlEPTB;MD6yNFghdk1? NFGyeIVUSU6JRWK=
no-10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO1UWNKSzVyPUCuNlEhdk1? MnfVV2FPT0WU
MMAC-SF MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMkG2JI5O MWfTRW5ITVJ?
A101D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7MXIJKSzVyPUCuNlI2KG6P NX7ISGl4W0GQR1XS
NTERA-S-cl-D1 NXno[pBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3QdFBKSzVyPUCuNlQ{KG6P MYfTRW5ITVJ?
8-MG-BA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMkWgcm0> NWn2cHVpW0GQR1XS
KNS-42 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vWNWlEPTB;MD6yOVghdk1? NUGyUol5W0GQR1XS
LXF-289 M1jCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMk[5JI5O NFP6TJpUSU6JRWK=
OVCAR-4 NVzQW4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvkS4Z2UUN3ME2wMlI5QSCwTR?= MUTTRW5ITVJ?
LOUCY NWLtW5hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXiTWM2OD1yLkK5N{BvVQ>? NYLzSVFnW0GQR1XS
BB65-RCC NVv6PYZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK4TWM2OD1yLkOwOEBvVQ>? MkPOV2FPT0WU
D-542MG M3i4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXSZXNiUUN3ME2wMlMzQSCwTR?= M{fhS3NCVkeHUh?=
ONS-76 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDQV4pKSzVyPUCuN|Mhdk1? NWr5TlhyW0GQR1XS
BB30-HNC Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwM{O1JI5O NWTObYxVW0GQR1XS
KS-1 NVO5V2lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLSN4tKSzVyPUCuN|Qhdk1? NGXmZnFUSU6JRWK=
A388 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PyeWlEPTB;MD6zOVYhdk1? NFTwc3NUSU6JRWK=
ES8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL1TWM2OD1yLkSgcm0> MlHXV2FPT0WU
MZ2-MEL M3v2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrUcpZKSzVyPUCuOFA4KG6P MYPTRW5ITVJ?
HCC2998 NXfIeJVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTTb5pKSzVyPUCuOFEzKG6P MWHTRW5ITVJ?
D-247MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPrTWM2OD1yLkSxN{BvVQ>? NWDqNGJKW0GQR1XS
ACN NUi2SY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PlbGlEPTB;MD60NVchdk1? NFvLXVZUSU6JRWK=
LB2518-MEL MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwNEK1JI5O M3LpSHNCVkeHUh?=
ES1 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mzdWlEPTB;MD60N{BvVQ>? MofuV2FPT0WU
HCE-T NX76R5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNEO5JI5O MnPLV2FPT0WU
OS-RC-2 NVLZc5A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvRZpKSzVyPUCuOFQhdk1? NWPUb5RDW0GQR1XS
MFH-ino MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTnN2lKSzVyPUCuOFQ{KG6P MnLHV2FPT0WU
OCUB-M NXrkdJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwNES3JI5O NFX4T5FUSU6JRWK=
CP66-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNEezJI5O NVGzdox4W0GQR1XS
LB771-HNC NGDlWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml36TWM2OD1yLkS3OEBvVQ>? M4X2NnNCVkeHUh?=
DSH1 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHJXZJzUUN3ME2wMlQ5KG6P MVnTRW5ITVJ?
HUTU-80 M4f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNUOzJI5O NXjz[YJJW0GQR1XS
CESS NX;X[3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnEUYo6UUN3ME2wMlU{QCCwTR?= NIj2b4hUSU6JRWK=
NCI-H747 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLObXJ[UUN3ME2wMlU{QSCwTR?= NHTieGpUSU6JRWK=
HT-144 NF;FelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rEeGlEPTB;MD61O|Yhdk1? M3HxVnNCVkeHUh?=
COLO-829 M3L1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0ZW9KSzVyPUCuOlE1KG6P MnfGV2FPT0WU
A4-Fuk NYPoc3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPJcXZUUUN3ME2wMlYzOyCwTR?= NHzrRohUSU6JRWK=
GI-ME-N MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvVS2lKSzVyPUCuOlM1KG6P MkL2V2FPT0WU
LB831-BLC MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe2TWM2OD1yLk[0NUBvVQ>? MWfTRW5ITVJ?
HOP-62 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW3TWM2OD1yLk[0O{BvVQ>? MVXTRW5ITVJ?
BB49-HNC NWL6Xm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OD1yLk[1NkBvVQ>? MWHTRW5ITVJ?
D-336MG NEP5S2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonhTWM2OD1yLk[1O{BvVQ>? NGLsSnBUSU6JRWK=
TK10 M3Tofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nuT2lEPTB;MD62O|khdk1? M3nafXNCVkeHUh?=
Ramos-2G6-4C10 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfzeXhkUUN3ME2wMlY6OyCwTR?= NVr5NGhpW0GQR1XS
LB373-MEL-D M{jPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTyOoRmUUN3ME2wMlchdk1? MVnTRW5ITVJ?
SF126 M3zJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;iTWM2OD1yLkewNUBvVQ>? MXTTRW5ITVJ?
UACC-257 M3PIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf2e|lKSzVyPUCuO|Ehdk1? MknFV2FPT0WU
KINGS-1 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwN{KyJI5O MVLTRW5ITVJ?
LS-513 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjV2VKSzVyPUCuO|M6KG6P MX;TRW5ITVJ?
GI-1 NF;4[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHxeXVKSzVyPUCuO|Y1KG6P MmXhV2FPT0WU
ES7 NYnhPYFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj1TWM2OD1yLke2OkBvVQ>? NFjObYFUSU6JRWK=
LB2241-RCC NUexUJY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Gc5ZKSzVyPUCuPFA1KG6P NUDoPZdQW0GQR1XS
D-263MG NXHmZ4JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[yWWlEPTB;MD64NFchdk1? MYnTRW5ITVJ?
SW684 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPHZWFPUUN3ME2wMlgzOSCwTR?= NWXUd21KW0GQR1XS
ML-2 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnXXGE6UUN3ME2wMlgzOSCwTR?= NHT2R21USU6JRWK=
SK-LMS-1 M2O4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXsTWM2OD1yLki1OEBvVQ>? MWjTRW5ITVJ?
TE-5 M2nsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwOE[1JI5O M13scnNCVkeHUh?=
QIMR-WIL NF[xd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETnVo9KSzVyPUCuPFg6KG6P Mn;LV2FPT0WU
NCI-H1355 NH3mNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33nWGlEPTB;MD64PVUhdk1? M3rqXnNCVkeHUh?=
SNB75 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHPTWM2OD1yLkmxNkBvVQ>? M3PvVHNCVkeHUh?=
RXF393 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP2TWM2OD1yLkmxOEBvVQ>? NEnBOHRUSU6JRWK=
IST-MEL1 M3niNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzETWRKSzVyPUCuPVE4KG6P NHjWPWZUSU6JRWK=
SF268 M17Vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq2TWM2OD1yLkmyN{BvVQ>? Mn:wV2FPT0WU
KALS-1 M3;jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfwTmo4UUN3ME2wMlkzPSCwTR?= MkTGV2FPT0WU
HC-1 M37COGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rV[2lEPTB;MD65O|Uhdk1? MlTkV2FPT0WU
SW872 M1rYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwOUm2JI5O Ml3qV2FPT0WU
PSN1 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LEXGlEPTB;MT6wNUBvVQ>? NV;hcm8xW0GQR1XS
TE-1 NFzY[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwMEOgcm0> NUT3eFJXW0GQR1XS
TE-10 NITDZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfFR29KSzVyPUGuNFMhdk1? MnfGV2FPT0WU
RKO MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvETWM2OD1zLkC2JI5O NHPUe2JUSU6JRWK=
LC-2-ad M1\yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX3[5BKSzVyPUGuNFghdk1? NIe2T2hUSU6JRWK=
SK-MM-2 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwMEmgcm0> MWHTRW5ITVJ?
VA-ES-BJ NVTzcVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfPUpRKSzVyPUGuNFkhdk1? M4PDWnNCVkeHUh?=
MZ7-mel MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwMEmgcm0> M3fC[nNCVkeHUh?=
D-392MG NUDue5FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j0XWlEPTB;MT6xJI5O NH\OVnhUSU6JRWK=
CCRF-CEM MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W5cGlEPTB;MT6xN{BvVQ>? NVXNR4N6W0GQR1XS
EM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu2dmlKSzVyPUGuNVYhdk1? NIHvZ4VUSU6JRWK=
HAL-01 M3f3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnkPJJKSzVyPUGuNVghdk1? MWrTRW5ITVJ?
TE-8 NWHsNHJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwMUmgcm0> MW\TRW5ITVJ?
NCI-H1882 NEmxXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomyTWM2OD1zLkKgcm0> MoLoV2FPT0WU
Daudi NGDIdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwMkKgcm0> NVvUSZl4W0GQR1XS
BL-41 M1nCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL5TWM2OD1zLkK1JI5O M1jhZnNCVkeHUh?=
SR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\1TFBtUUN3ME2xMlI2KG6P NFvWS4NUSU6JRWK=
KM12 Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwMkegcm0> MYrTRW5ITVJ?
K5 NH;QR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe4TZJFUUN3ME2xMlI5KG6P M{jQN3NCVkeHUh?=
A3-KAW NUDX[4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOzRoJKSzVyPUGuNlghdk1? NIjjTodUSU6JRWK=
CMK NWX6XZI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\l[2kzUUN3ME2xMlI6KG6P NXXZXI5wW0GQR1XS
Calu-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXwdG1KSzVyPUGuNlkhdk1? NHPzPZpUSU6JRWK=
IST-SL2 NYW3RXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3sTWM2OD1zLkOxJI5O MlHJV2FPT0WU
OPM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXvbnhIUUN3ME2xMlM{KG6P M{SyeHNCVkeHUh?=
DU-4475 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfHTWM2OD1zLkO2JI5O MYHTRW5ITVJ?
ECC12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfW[YtKSzVyPUGuN|chdk1? NH7D[lBUSU6JRWK=
L-540 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXITWM2OD1zLkO3JI5O MWHTRW5ITVJ?
CAS-1 NULZdnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTNTWM2OD1zLkO3JI5O NHnwSHFUSU6JRWK=
PF-382 NFPEXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPn[ldKSzVyPUGuOFchdk1? Ml\WV2FPT0WU
LS-411N NE\3NYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn6TWM2OD1zLkWzJI5O NHmxdXlUSU6JRWK=
NCI-H69 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nSWWlEPTB;MT61OEBvVQ>? NVnxPHpCW0GQR1XS
NB12 Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnH[lZKSzVyPUGuOVYhdk1? NXn0NGZ2W0GQR1XS
HEL M2rJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHnTWM2OD1zLk[xJI5O M2jneXNCVkeHUh?=
GCIY M3LQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW2dmpIUUN3ME2xMlYzKG6P M{LvRnNCVkeHUh?=
EHEB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwNkegcm0> NV3QVZgyW0GQR1XS
TGBC1TKB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jhXGlEPTB;MT63NUBvVQ>? MkPHV2FPT0WU
KURAMOCHI NVX4Z2xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4noS2lEPTB;MT63NkBvVQ>? MnPiV2FPT0WU
U-266 NIfLXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTSN2JiUUN3ME2xMlc3KG6P Ml3DV2FPT0WU
LC4-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwN{mgcm0> NG[3fm9USU6JRWK=
NCI-H2126 M4XP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4eWd2UUN3ME2xMlghdk1? MoPOV2FPT0WU
NCI-H1092 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwODDuUS=> NXfTdGtMW0GQR1XS
GB-1 M3q5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljvTWM2OD1zLkixJI5O M2Hmb3NCVkeHUh?=
MV-4-11 NWfXfIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzNTWM2OD1zLkiyJI5O NF7WWVdUSU6JRWK=
Becker MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzoWXZKSzVyPUGuPFMhdk1? MXnTRW5ITVJ?
MPP-89 NWS3VotVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLHTWM2OD1zLki5JI5O MoDtV2FPT0WU
BE-13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW2TWM2OD1zLkmzJI5O MlPGV2FPT0WU
697 M1Lmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljiTWM2OD1zLkm5JI5O NWi4NYxuW0GQR1XS
NKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT6O3ZKSzVyPUKgcm0> MkPDV2FPT0WU
NB13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30NWVKSzVyPUKgcm0> M{XNZXNCVkeHUh?=
LS-123 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTPfpVvUUN3ME2yMlAzKG6P MlfxV2FPT0WU
NB17 NXLjUHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTw[ZRKSzVyPUKuNFQhdk1? M{\0OXNCVkeHUh?=
LAN-6 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwMEWgcm0> M3zNfnNCVkeHUh?=
EW-24 M3jicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;4UlVYUUN3ME2yMlA5KG6P NYP3S2dKW0GQR1XS
NOS-1 M2\OS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXoe3ZKSzVyPUKuNVEhdk1? NUK2WoVnW0GQR1XS
BL-70 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K4VmlEPTB;Mj6xNkBvVQ>? MmLhV2FPT0WU
GT3TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfCRoFKSzVyPUKuNVIhdk1? M2fHNHNCVkeHUh?=
HH MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TDTGlEPTB;Mj6xN{BvVQ>? NWeybppXW0GQR1XS
KE-37 NWPqfXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvETWM2OD1{LkGzJI5O M375PXNCVkeHUh?=
MOLT-4 NWP2OWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Z[XhKSzVyPUKuNVMhdk1? M1XK[XNCVkeHUh?=
EKVX MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPZcllKSzVyPUKuNVQhdk1? MnjIV2FPT0WU
KGN MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMUWgcm0> NHG2W3RUSU6JRWK=
ES4 M1K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLJTmJ7UUN3ME2yMlE3KG6P NIjoO21USU6JRWK=
SJSA-1 NIrMUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwMkGgcm0> NUHFTHM5W0GQR1XS
KMOE-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH3TWM2OD1{LkKzJI5O MmPhV2FPT0WU
NB5 NXHjXnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnwTZp1UUN3ME2yMlI4KG6P M1HPVnNCVkeHUh?=
BC-1 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwM{Ggcm0> NXXXV|RnW0GQR1XS
NB10 M{jhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnLTm5CUUN3ME2yMlMzKG6P NGqzbGdUSU6JRWK=
RPMI-8226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq1TFZKSzVyPUKuN|Uhdk1? NGHye3JUSU6JRWK=
SCC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwM{egcm0> NIS1XGZUSU6JRWK=
ARH-77 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJwM{igcm0> NVnHPZdkW0GQR1XS
NCI-H748 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwM{mgcm0> MnTyV2FPT0WU
KU812 NGm4eVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjlXG5lUUN3ME2yMlQzKG6P M{LINXNCVkeHUh?=
NCI-H64 NXnrdHlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O3ZmlEPTB;Mj60OEBvVQ>? NET5XJFUSU6JRWK=
NB69 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvqTWM2OD1{LkS2JI5O M2jxVHNCVkeHUh?=
KNS-81-FD NXHhO5BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwNEigcm0> M2TTNnNCVkeHUh?=
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\BVGlEPTB;Mj61O{BvVQ>? MXXTRW5ITVJ?
EB-3 MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX1TWM2OD1{Lk[2JI5O M4W1cnNCVkeHUh?=
Mo-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnMbJpFUUN3ME2yMlc1KG6P M1;oSnNCVkeHUh?=
EW-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwN{Wgcm0> NUDsfW9KW0GQR1XS
CTV-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnNOoN5UUN3ME2yMlghdk1? NHHMPYtUSU6JRWK=
ETK-1 M3rnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[4T3VVUUN3ME2yMlg1KG6P M4flWnNCVkeHUh?=
C2BBe1 NIC5botIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXVNo9KSzVyPUKuPFkhdk1? NELQU5dUSU6JRWK=
MOLT-16 M2P6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG2eXlJUUN3ME2yMlg6KG6P NWLwVHNNW0GQR1XS
SW954 NIT3cIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rzTGlEPTB;Mj65JI5O M1z5RXNCVkeHUh?=
HT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjhTWM2OD1|LkCyJI5O MWfTRW5ITVJ?
KARPAS-299 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOzTWM2OD1|LkC2JI5O MYLTRW5ITVJ?
MONO-MAC-6 NHHCUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwMTDuUS=> NFzseFRUSU6JRWK=
CGTH-W-1 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLnfXNQUUN3ME2zMlEhdk1? MXnTRW5ITVJ?
SK-PN-DW MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DQZ2lEPTB;Mz6xOEBvVQ>? NX21NmJVW0GQR1XS
CW-2 NYjMd|R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD1|LkKxJI5O MorIV2FPT0WU
SK-N-DZ NHjycYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwMk[gcm0> M1n1[nNCVkeHUh?=
NEC8 M{\PXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwM{Wgcm0> NHHnNm1USU6JRWK=
LB996-RCC NInXNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwNDDuUS=> NIHjUnBUSU6JRWK=
DB MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\1TWM2OD1|LkSxJI5O MULTRW5ITVJ?
TE-15 NVLSZnQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHtWHlKSzVyPUOuOFMhdk1? NHnEUppUSU6JRWK=
COR-L88 M2nZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwNEegcm0> M1v5eHNCVkeHUh?=
LAMA-84 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17zO2lEPTB;Mz60PUBvVQ>? NUTwemlRW0GQR1XS
MEG-01 NUf5RnBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnXTmpwUUN3ME2zMlQ6KG6P M3;PSHNCVkeHUh?=
LOXIMVI NUnsU|N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwNTDuUS=> NEDJcGdUSU6JRWK=
RPMI-8402 M2jRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq4Z29KSzVyPUOuOUBvVQ>? NX76ZWxvW0GQR1XS
KARPAS-45 M4[5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrsTWM2OD1|LkW0JI5O MnfEV2FPT0WU
HCC1187 NU\DSGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDnTWM2OD1|LkW0JI5O MXXTRW5ITVJ?
MZ1-PC Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrlTFl7UUN3ME2zMlU1KG6P M2Tj[XNCVkeHUh?=
no-11 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPpNVVKSzVyPUOuOVUhdk1? MWjTRW5ITVJ?
EVSA-T M1LCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fH[WlEPTB;Mz62JI5O NYjHO3E1W0GQR1XS
DJM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWewd3pTUUN3ME2zMlY{KG6P NEPiSYVUSU6JRWK=
COLO-684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DkO2lEPTB;Mz62OkBvVQ>? NVGwZmtyW0GQR1XS
NMC-G1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwNkigcm0> NEPKVZZUSU6JRWK=
LC-1F MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLKfFNKSzVyPUOuO|Qhdk1? M1PpW3NCVkeHUh?=
RL95-2 NVfZOVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLJXY9jUUN3ME2zMlc6KG6P M3qzSHNCVkeHUh?=
COLO-320-HSR M3nKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TGcmlEPTB;Mz65NkBvVQ>? Ml7xV2FPT0WU
RCC10RGB M1nuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwOUOgcm0> NYHrUFRTW0GQR1XS
HD-MY-Z MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjYVJNKSzVyPUOuPVMhdk1? M{LEPXNCVkeHUh?=
NCI-H2141 M4HZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[5VGlEPTB;ND6wOUBvVQ>? M1vrXHNCVkeHUh?=
K-562 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW1TWM2OD12LkGyJI5O M1P1bHNCVkeHUh?=
NCI-H1648 M3qyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljwTWM2OD12LkGzJI5O MnzZV2FPT0WU
OMC-1 M3;BOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTRwMUigcm0> MW\TRW5ITVJ?
LB647-SCLC NIDWSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn6S2ZtUUN3ME20MlIzKG6P MVPTRW5ITVJ?
TE-12 NHT5XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfSZYdKSzVyPUSuNlUhdk1? NEPlUlhUSU6JRWK=
NOMO-1 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:5fJpCUUN3ME20MlM{KG6P NF\v[WVUSU6JRWK=
Raji MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;N[m9FUUN3ME20MlQ3KG6P M4jWZXNCVkeHUh?=
NALM-6 M3XzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq2TWM2OD12LkS5JI5O M3LaRnNCVkeHUh?=
HL-60 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTRwNkegcm0> Mn3wV2FPT0WU
IST-SL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHIPYY4UUN3ME20MlY5KG6P NHvXcY5USU6JRWK=
MHH-PREB-1 NYnOXpZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTRwOE[gcm0> MVrTRW5ITVJ?
MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TEW2lEPTB;ND65NUBvVQ>? NIO4fmlUSU6JRWK=
JiyoyeP-2003 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGybYlLUUN3ME21JI5O NWDU[HRZW0GQR1XS
SBC-1 NWW5S4JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LL[GlEPTB;NT6wNUBvVQ>? M4PPSnNCVkeHUh?=
CHP-126 M4nleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fLN2lEPTB;NT6wOkBvVQ>? NHWxeItUSU6JRWK=
LU-139 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17afGlEPTB;NT6xN{BvVQ>? MWPTRW5ITVJ?
NCI-SNU-5 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzWTWM2OD13LkG3JI5O NFi0[2RUSU6JRWK=
SW962 NYDaUHViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfxPHJHUUN3ME21MlIyKG6P NVi5[pBPW0GQR1XS
EW-1 M3rlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTVwM{Ggcm0> MlvQV2FPT0WU
NCI-H1417 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvke4JKSzVyPUWuOVEhdk1? Mn\mV2FPT0WU
LU-65 NYnmTHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDL[YNFUUN3ME21Mlg1KG6P M4\HenNCVkeHUh?=
D-502MG NYTDPYVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZwM{egcm0> NX\wSJdDW0GQR1XS
BC-3 M{Tmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDSeFNKSzVyPU[uOlEhdk1? M1HYd3NCVkeHUh?=
GDM-1 M1Pt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm2T2FpUUN3ME22Mlc4KG6P NGj4UYZUSU6JRWK=
NCI-H2196 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTZwODDuUS=> NEXTcGFUSU6JRWK=
NB1 NXu0bWlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi5ZnBYUUN3ME22Mlg5KG6P MW\TRW5ITVJ?
NCI-H345 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG5TWM2OD15LkKgcm0> M1rrT3NCVkeHUh?=
SU-DHL-1 NYHyR41bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdwMkSgcm0> MoLtV2FPT0WU
JVM-2 M4\iWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13LO2lEPTB;Nz6yPEBvVQ>? NIK4ZnVUSU6JRWK=
LU-134-A MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzzUmNKSzVyPUeuN|khdk1? MlHsV2FPT0WU
NCI-H1694 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXDTWM2OD15LkW4JI5O NX\wXHlOW0GQR1XS
NCI-SNU-16 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSyTWM2OD15Lk[1JI5O M2fEU3NCVkeHUh?=
L-363 NE\ZVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLETWM2OD15Lkegcm0> M1zmOnNCVkeHUh?=
KG-1 NWrmd|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rHfGlEPTB;Nz65OEBvVQ>? MlLkV2FPT0WU
MN-60 NGPmUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq2TWM2OD16LkG0JI5O NF3mNmVUSU6JRWK=
NB6 NV:1c|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjOTWM2OD16LkS4JI5O NYHJd4xuW0GQR1XS
MLMA Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13DOWlEPTB;OD64OUBvVQ>? NXjTOGxzW0GQR1XS
ATN-1 NVvxXGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HodmlEPTB;OD64PUBvVQ>? M33vcnNCVkeHUh?=
SK-NEP-1 M3zSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwMEGgcm0> NUTvOoJDW0GQR1XS
DMS-114 NGDZemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELGR5NKSzVyPUmuOlIhdk1? NHjFPJZUSU6JRWK=
CTB-1 NVPJT3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfmTWM2OD17Lk[3JI5O MlPTV2FPT0WU
NCI-H2081 NWHFS2h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;YOI1KSzVyPUGwMlA6KG6P MXvTRW5ITVJ?
ES5 M1XYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFyLkO4JI5O Mk\XV2FPT0WU
HCC1599 NIrKWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTxVppvUUN3ME2xNU46OSCwTR?= NYTadZd6W0GQR1XS
NCI-H23 NHvFXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGw[Xk5UUN3ME2xNk4yOiCwTR?= MYHTRW5ITVJ?
NCI-H1581 M4\oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF{LkK4JI5O NV;kc444W0GQR1XS
JVM-3 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF{Lkm5JI5O NGr1c3pUSU6JRWK=
NCI-SNU-1 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF|LkG5JI5O Mnq4V2FPT0WU
NB7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDhTWM2OD1zNT65NkBvVQ>? M1\2RnNCVkeHUh?=
JAR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG4e4FKSzVyPUG2MlE{KG6P MkDOV2FPT0WU
TGW NIficGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF4LkS4JI5O M2PyeXNCVkeHUh?=
U-87-MG MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\OWok1UUN3ME2xOk44PiCwTR?= MWnTRW5ITVJ?
NCI-H1436 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF5LkCxJI5O MoT6V2FPT0WU
GOTO MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CxUmlEPTB;MUeuNFYhdk1? M17PXHNCVkeHUh?=
COLO-800 NWX6NXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF5Lk[0JI5O MWPTRW5ITVJ?
MFM-223 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r5fWlEPTB;MUeuPVEhdk1? MoT3V2FPT0WU
EW-18 NGDz[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF5Lkm2JI5O MmnBV2FPT0WU
NB14 NGLSe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPLTWM2OD1zNz65PEBvVQ>? Mn3hV2FPT0WU
EB2 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK5R2dKSzVyPUG4MlA5KG6P NW\5cJdJW0GQR1XS
EoL-1- Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF6LkOxJI5O M1nZT3NCVkeHUh?=
NCCIT MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qWWlEPTB;MUiuN|Yhdk1? NF7VOFdUSU6JRWK=
DG-75 M4fMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF6Lk[xJI5O NFLRVGZUSU6JRWK=
HCC2218 NYH2Uos1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnUXIp4UUN3ME2xPU42KG6P MoPzV2FPT0WU
TE-6 NEG4OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;2fHdKSzVyPUKwMlA5KG6P M4W0WnNCVkeHUh?=
SF539 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvpTWM2OD1{MD62O{BvVQ>? NFTncJJUSU6JRWK=
NCI-H446 M2\6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DrT2lEPTB;MkGuNVghdk1? M1rybXNCVkeHUh?=
IST-MES1 NXTyPHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;2T2lEPTB;MkKuO|chdk1? NE\5fnpUSU6JRWK=
NCI-H82 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCzSodLUUN3ME2yN{4xOiCwTR?= NWnjcYk1W0GQR1XS
HCC2157 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHlTWM2OD1{Mz6xN{BvVQ>? M{Hv[3NCVkeHUh?=
EW-12 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ|LkG3JI5O M4\WRXNCVkeHUh?=
SIMA MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHhTWM2OD1{Mz6zPEBvVQ>? MUDTRW5ITVJ?
DOHH-2 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XmZWlEPTB;MkOuOFUhdk1? MnvVV2FPT0WU
IM-9 M1rhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ|LkW0JI5O M1PDU3NCVkeHUh?=
EC-GI-10 NVrYfJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULtO|ZwUUN3ME2yOE4zOyCwTR?= NXXmbYJGW0GQR1XS
HDLM-2 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCzXZNiUUN3ME2yOE42PCCwTR?= NVHtOoplW0GQR1XS
LS-1034 NF;RfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTOUZZKSzVyPUK1Mlc2KG6P NYfRXG9[W0GQR1XS
REH MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrzTWM2OD1{Nj60NUBvVQ>? M4r0SnNCVkeHUh?=
LU-165 NXPOTXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPRNJdKSzVyPUK2MlczKG6P MmjkV2FPT0WU
NH-12 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrzcHZVUUN3ME2yO{43PyCwTR?= Mnu1V2FPT0WU
WSU-NHL NILjOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG2TWM2OD1{OD6zPUBvVQ>? NH;rPYFUSU6JRWK=
ECC4 M1XHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHiTWM2OD1{OD63PUBvVQ>? MkPTV2FPT0WU
OCI-AML2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjqOGlKSzVyPUK5MlY6KG6P MVTTRW5ITVJ?
EW-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNyLkW5JI5O MX3TRW5ITVJ?
NCI-H526 M{[4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli4TWM2OD1|Mj61OEBvVQ>? M1;NcXNCVkeHUh?=
NCI-H719 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN2LkOxJI5O M4HPeHNCVkeHUh?=
KARPAS-422 NF3r[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHWO|VKSzVyPUO1MlA1KG6P Mm\0V2FPT0WU
SK-MEL-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX1bVF1UUN3ME2zOU4yPyCwTR?= MWjTRW5ITVJ?
ES3 NELtfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfmS|JKSzVyPUO1MlE6KG6P MXHTRW5ITVJ?
UACC-812 NX7sU2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjmV285UUN3ME2zOU41PCCwTR?= MnvCV2FPT0WU
C8166 M4fBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvaTWM2OD1|NT63JI5O MmTpV2FPT0WU
MDA-MB-134-VI NIPoVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN3Lki3JI5O Ml3kV2FPT0WU
D-283MED M1jh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorITWM2OD1|Nz63PUBvVQ>? MWfTRW5ITVJ?
SHP-77 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PUOGlEPTB;M{iuNFMhdk1? NXywdZY5W0GQR1XS
NCI-H2227 NVrsfHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fhbGlEPTB;NECuOFkhdk1? NGHleXpUSU6JRWK=
SKM-1 NIPNcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny4TWM2OD12Mj62N{BvVQ>? NGjoR2VUSU6JRWK=
L-428 NU\XRo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\TWGtTUUN3ME20N{45PiCwTR?= MnzKV2FPT0WU
RPMI-6666 M{fJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPTWM2OD12NT64PUBvVQ>? MVjTRW5ITVJ?
NCI-H716 MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13Ye2lEPTB;NEiuPFEhdk1? MnixV2FPT0WU
DMS-79 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfwWoQ6UUN3ME21NE44OSCwTR?= NIH3dYdUSU6JRWK=
RS4-11 M3XoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjkWGVKSzVyPUWwMlg5KG6P MkXjV2FPT0WU
NCI-H720 M4T3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HVGlEPTB;NUGuNVEhdk1? M1rObnNCVkeHUh?=
MC-CAR NUOwT|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HFbGlEPTB;NUGuOVIhdk1? NEDkXXVUSU6JRWK=
TALL-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4eyTWlEPTB;NUOuPVEhdk1? M1\TWXNCVkeHUh?=
NCI-N87 NYTVPWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVflUnA2UUN3ME21OE4yQCCwTR?= NWXROJdDW0GQR1XS
P30-OHK MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHORllHUUN3ME21OE43OSCwTR?= M1;4dHNCVkeHUh?=
LP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZzLkK4JI5O NFPoN5VUSU6JRWK=
YT NVr5TFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTZzLkigcm0> MVTTRW5ITVJ?
MRK-nu-1 M{W3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G3cGlEPTB;NkGuPFIhdk1? MYrTRW5ITVJ?
BT-474 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnle5hKSzVyPU[1JI5O M1LEXHNCVkeHUh?=
NCI-H322M NWW5PXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HGd2lEPTB;Nk[uNVEhdk1? M{\3SnNCVkeHUh?=
NCI-H128 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HYV2lEPTB;N{SuO|chdk1? NWqwdphlW0GQR1XS
KMS-12-PE MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPVe49KSzVyPUe2MlI1KG6P M{HRcHNCVkeHUh?=
KP-N-YS NH64OWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi4UI9oUUN3ME23Ok44PCCwTR?= MVPTRW5ITVJ?
ALL-PO M4jZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTd5Lk[2JI5O Mk\KV2FPT0WU
EW-13 NIDZWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvHZZhFUUN3ME23O{44PiCwTR?= NFzKOldUSU6JRWK=
EW-11 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHTPFJ2UUN3ME23PE42OiCwTR?= NXXsNGl6W0GQR1XS
SK-N-FI NIC4PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O4OmlEPTB;OECuNkBvVQ>? NFHzXpZUSU6JRWK=
CAL-148 NEiyXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRThzLki0JI5O NYPJcW5JW0GQR1XS
RL MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLPTWM2OD16Nj6wPUBvVQ>? M{\pd3NCVkeHUh?=
AM-38 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTh6LkC4JI5O NXnL[GpNW0GQR1XS
RH-1 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTl7Lki1JI5O MVTTRW5ITVJ?
NCI-H1770 NFX2NnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfxb2o5UUN3ME2xNFIvPDlibl2= NVXzOGxpW0GQR1XS
SIG-M5 NVO2OXZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W2VmlEPTB;MUC1MlA3KG6P NFfheJZUSU6JRWK=
GR-ST MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6zdYRKSzVyPUGxN{4{PCCwTR?= MWTTRW5ITVJ?
ST486 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHlTWM2OD1zMUSuNFYhdk1? NF\NZ4xUSU6JRWK=
NCI-H1650 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPiWFlTUUN3ME2xNVUvOjlibl2= MUXTRW5ITVJ?
MHH-CALL-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC0Z3Z{UUN3ME2xNVUvPyCwTR?= NYPUc5JiW0GQR1XS
BV-173 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rS[mlEPTB;MUKyMlcyKG6P M2fOcHNCVkeHUh?=
MC116 NEO5NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\wbFNKSzVyPUG0PE45PSCwTR?= MkjhV2FPT0WU
NCI-H524 NWm5XmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j5OGlEPTB;MUW5MlEhdk1? NEG5b3lUSU6JRWK=
SCLC-21H M1zr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj2cndKSzVyPUG1PU41OSCwTR?= MXTTRW5ITVJ?
NCI-H1304 M{LxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vnPGlEPTB;MU[5MlIyKG6P MWrTRW5ITVJ?
NCI-H510A NIXTO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF6NT6zO{BvVQ>? M{jHeXNCVkeHUh?=
NCI-H209 NUfKbIZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHvcoZuUUN3ME2xPVYvPTJibl2= NVXlWpk5W0GQR1XS
KM-H2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF7Nz6wOUBvVQ>? NIr2[W9USU6JRWK=
NCI-H1395 NFu3XnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3Z[4lKSzVyPUKxNE4yOyCwTR?= NWLYSllWW0GQR1XS
NCI-H1155 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjNS2hKSzVyPUKzNE4{OiCwTR?= NH31bndUSU6JRWK=
COR-L279 NHnpfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ3Mj6xO{BvVQ>? NUjTV4sxW0GQR1XS
NCI-H1299 NUn0[283T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXPTJdjUUN3ME2yOlEvPzFibl2= NVHi[3ZGW0GQR1XS
EW-22 NHrpWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r1dGlEPTB;Mk[zMlc2KG6P M2PVOnNCVkeHUh?=
SK-MEL-2 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ6MT65JI5O M{HHWnNCVkeHUh?=
KASUMI-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXoTItKSzVyPUK4N{4xPSCwTR?= NVLES21WW0GQR1XS
NCI-H187 M1XsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPRTWM2OD1{OEeuNFghdk1? MWPTRW5ITVJ?
NCI-H2171 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XKN2lEPTB;Mki4MlkzKG6P NH;Cd2VUSU6JRWK=
LNCaP-Clone-FGC M2LYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGe2lEPTB;Mkm1MlI3KG6P NXzHfodnW0GQR1XS
NCI-H1522 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\aTWM2OD1|MEeuNFUhdk1? MkP4V2FPT0WU
SCH NIL1UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH1folKSzVyPUOyNk4zOiCwTR?= MlHRV2FPT0WU
THP-1 NWHjbJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LzUWlEPTB;M{KyMlYhdk1? NVPnR3JzW0GQR1XS
SNU-C1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfCboVFUUN3ME2zOlIvODlibl2= MmDTV2FPT0WU
CA46 NWfO[2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3TWM2OD1|N{OuOlMhdk1? NHO5UFJUSU6JRWK=
NCI-H1963 NYLqWod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvoe5pKSzVyPUO4Ok4yQSCwTR?= NV7IWJhoW0GQR1XS
DEL NIHUPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN7MT6yO{BvVQ>? M3\IPXNCVkeHUh?=
TUR NEPEV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmToJjUUN3ME2zPVYvPjFibl2= MlL6V2FPT0WU
NCI-H226 NVTab3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn73TWM2OD12MEOuNlMhdk1? NHfGbJpUSU6JRWK=
COLO-668 NVLsVVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml75TWM2OD12MEOuOVchdk1? MlnWV2FPT0WU
CPC-N NXS0T5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRyMz63O{BvVQ>? NEDjdG5USU6JRWK=
NCI-H889 NULObJVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn6PGRKSzVyPUS2NU46OiCwTR?= NWX2NlVVW0GQR1XS
J-RT3-T3-5 NVfqNGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\2c2hKSzVyPUWzNk42PyCwTR?= NEDq[mtUSU6JRWK=
MSTO-211H NVP0dGhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPtXVF{UUN3ME21O|QvOjZibl2= M37PcXNCVkeHUh?=
SCC-15 NV;kZoFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZ4Nz60O{BvVQ>? M2XB[XNCVkeHUh?=
SUP-T1 NWf0NJlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfITWM2OD14OE[uNFQhdk1? NH\3S|VUSU6JRWK=
DMS-153 NUTObHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTd2Nj64N{BvVQ>? M1v2RnNCVkeHUh?=
MS-1 M1nCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS0TWM2OD15NUmuOFIhdk1? MnjlV2FPT0WU
TC-YIK MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTwblJKSzVyPUe4NU4xOSCwTR?= NWXTb4FbW0GQR1XS
RPMI-8866 M3XqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljFTWM2OD1zMEC2MlI5KM7:TR?= M3vLS3NCVkeHUh?=
KY821 NHe4RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHyUJNKSzVyPUGwN|YvODRizszN MWXTRW5ITVJ?
P31-FUJ M37u[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrBT3BUUUN3ME2xNVEzNjd3IN88US=> M2HVenNCVkeHUh?=
COLO-824 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHFTWM2OD1zMk[xMlc5KM7:TR?= M1jwcnNCVkeHUh?=
U-698-M NGHkUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDPTWM2OD1{Mk[yMlE2KM7:TR?= MmHEV2FPT0WU
TE-441-T Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPG[pBKSzVyPUK1NlEvPyEQvF2= MWTTRW5ITVJ?
IMR-5 NGnqW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7CRo1QUUN3ME2zOFA6NjZ{IN88US=> MXzTRW5ITVJ?
NCI-H1838 M2X3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfDfWhxUUN3ME20NVg3NjN{IN88US=> NIXpelRUSU6JRWK=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
- Collapse

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
- Collapse
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341
Smiles B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03993262 Recruiting Drug: Bortezomib|Drug: Placebo Autoimmune Encephalitis Jena University Hospital May 13 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.

  • Ixazomib (MLN2238)

    Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol (Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID